Jun 12

Marcel Wolbers.

Treatment with amphotericin fluconazole and B did not confer a survival advantage, in comparison with monotherapy. There was no factor in survival between the two combination-treatment groups. Nevertheless, after adjustment for baseline covariates, combination therapy with flucytosine was associated with a lower life expectancy hazard of death, in comparison with amphotericin B alone or with amphotericin B in addition fluconazole . The multivariable Cox regression identified the next independent predictors of 6-month survival: baseline fungal count and a score on the Glasgow Coma Scale of less than 15 .All individuals underwent a baseline medical evaluation that included posteroanterior upper body radiography, being pregnant testing if relevant, assortment of two sputum specimens for microbiologic exam, physical examination, exams of visual acuity , and urinalysis. All analyses were performed based on the REMoxTB laboratory and quality manuals . We performed mycobacterial speciation using the AccuProbe assay , and established the susceptibility of strains to streptomycin, isoniazid, rifampin, and pyrazinamide using the MGIT manufacturer’s instructions.